Skip to main content

Table 1 Association between RECQL mRNA Expression and Clinicopathologic Characteristics (N = 774)

From: Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients

Characteristic No. RECQL mRNA expression P
Low High
No. % No. %
Total 774 387 50.0 387 50.0  
Age       
  ≤ 50 yr 331 168 43.4 163 42.1 0.72
  > 50 yr 443 219 56.6 224 57.9  
Tumor size       
  ≤ 2 cm 298 142 36.7 156 40.3 0.30
  > 2 cm 476 245 63.3 231 59.7  
Tumor grade       
 I 186 85 22.7 101 26.6 0.041
 II 443 215 57.5 228 60.2  
 III 124 74 19.8 50 13.2  
 Unknown 21 13   8   
Lymph node status       
 Negative 510 239 65.5 271 73.0 0.026
 Positive 226 126 34.5 100 27.0  
 Unknown 38 22   16   
ER status       
 Negative 223 124 32.1 99 25.6 0.047
 Positive 549 262 67.9 287 74.4  
 Unknown 2 1   1   
PR status       
 Negative 302 160 42.0 142 37.1 0.16
 Positive 462 221 58.0 241 62.9  
 Unknown 10 6   4   
HER2 status       
 Negative 556 254 66.0 302 78.2 < 0.001
 Positive 215 131 34.0 84 21.8  
 Unknown 3 2   1   
Ki-67       
 High 445 233 62.3 212 55.9 0.08
 Low 308 141 37.7 167 44.1  
 Unknown 21 13   8   
Subtype       
 Luminal A 173 76 19.8 97 25.1 0.003
 Luminal B(HER2-) 268 119 30.1 149 38.6  
 Luminal B(HER2+) 123 78 20.3 45 11.7  
 HER2+ 92 53 13.8 39 10.1  
 TN 114 58 15.1 56 14.5  
 Unknown 4 3   1   
Adjuvant Therapy       
 C 157 83 21.4 74 19.1 0.011
 E 281 121 31.3 160 41.3  
 C + E 245 127 32.8 118 30.5  
 No therapy 91 56 14.5 35 9.0  
Trastuzumab use       
 No 739 372 96.1 367 94.8 0.39
 Yes 35 15 3.9 20 5.2  
Surgery type       
 BCS 294 137 37.4 157 42.1 0.20
 Mastectomy 445 229 62.6 216 57.9  
 Unknown 35 21   14   
  1. Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; TN, triple negative; C, chemotherapy; E, endocrinotherapy; C + E, chemotherapy and endocrinotherapy; BCS, breast-conserving surgery
  2. Comments: luminal A: ER+ or PR ≥ 20%, HER2-, Ki-67 < 14%; luminal B (HER2-): ER+ and HER2-, Ki-67 ≥ 14% or PR−/< 20%, luminal B (HER2+): ER+ and HER2+; HER2(+): ER- and PR-, HER2+; TN: ER- and PR-, HER2-